Literature DB >> 11170455

Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP.

X Be1, Y Hong, J Wei, E J Androphy, J J Chen, J D Baleja.   

Abstract

E6AP is a cellular protein that binds cancer-related papillomaviral E6 proteins. The E6 binding domain, called E6ap, is located on an 18-amino acid segment of E6AP. The corresponding peptide was synthesized and its structure determined by nuclear magnetic resonance spectroscopy. The overall structure of the peptide is helical. A consensus E6-binding sequence among different E6 interacting proteins contains three conserved hydrophobic residues. In the structure of the E6AP peptide, the three conserved leucines (Leu 9, Leu 12, and Leu 13) form a hydrophobic patch on one face of the alpha-helix. Substitution of any of these leucines with alanine abolished binding to E6 protein, indicating that the entire hydrophobic patch is necessary. Mutation of a glutamate to proline, but not alanine, also disrupted the interaction between E6 and E6AP protein, suggesting that the E6-binding motif of the E6AP protein must be helical when bound to E6. Comparison of the E6ap structure and mutational results with those of another E6-binding protein (E6BP/ERC-55) indicates the existence of a general E6-binding motif.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170455     DOI: 10.1021/bi0019592

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

2.  A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo.

Authors:  Marie Nguyen; Shiyu Song; Amy Liem; Elliot Androphy; Yun Liu; Paul F Lambert
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  A conserved amphipathic helix in the N-terminal regulatory region of the papillomavirus E1 helicase is required for efficient viral DNA replication.

Authors:  Geneviève Morin; Amélie Fradet-Turcotte; Paola Di Lello; Fanny Bergeron-Labrecque; James G Omichinski; Jacques Archambault
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

4.  Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.

Authors:  James D Baleja; Jonathan J Cherry; Zhiguo Liu; Hua Gao; Marc C Nicklaus; Johannes H Voigt; Jason J Chen; Elliot J Androphy
Journal:  Antiviral Res       Date:  2006-04-21       Impact factor: 5.970

5.  The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Folding and misfolding of the papillomavirus E6 interacting peptide E6ap.

Authors:  Bianxiao Cui; Min-Yi Shen; Karl F Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-27       Impact factor: 11.205

Review 7.  Papillomavirus E6 proteins.

Authors:  Heather L Howie; Rachel A Katzenellenbogen; Denise A Galloway
Journal:  Virology       Date:  2008-12-10       Impact factor: 3.616

8.  The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo.

Authors:  Marie L Nguyen; Minh M Nguyen; Denis Lee; Anne E Griep; Paul F Lambert
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 9.  Recent advances in the search for antiviral agents against human papillomaviruses.

Authors:  Amélie Fradet-Turcotte; Jacques Archambault
Journal:  Antivir Ther       Date:  2007

10.  Determinants of stability for the E6 protein of papillomavirus type 16.

Authors:  Yuqi Liu; Jonathan J Cherry; Joseph V Dineen; Elliot J Androphy; James D Baleja
Journal:  J Mol Biol       Date:  2009-03-06       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.